Artelo Biosciences (NASDAQ:ARTL) Stock Price Down 3.7% – Should You Sell?

Artelo Biosciences, Inc. (NASDAQ:ARTL) shares traded down 3.7% during trading on Tuesday . The stock traded as low as $1.01 and last traded at $1.06. 37,580 shares were traded during mid-day trading, a decline of 73% from the average session volume of 136,752 shares. The stock had previously closed at $1.10.

Analysts Set New Price Targets

ARTL has been the topic of a number of research analyst reports. D. Boral Capital reiterated a “buy” rating and set a $6.00 target price on shares of Artelo Biosciences in a report on Monday, April 28th. HC Wainwright restated a “buy” rating and set a $5.00 price target on shares of Artelo Biosciences in a research report on Tuesday, March 4th.

Artelo Biosciences Stock Performance

The company has a market capitalization of $3.47 million, a PE ratio of -0.37 and a beta of 1.03. The business’s 50-day moving average is $0.97 and its 200-day moving average is $1.06.

Artelo Biosciences (NASDAQ:ARTL) last released its earnings results on Tuesday, May 13th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.59). Analysts expect that Artelo Biosciences, Inc. will post -2.62 EPS for the current year.

About Artelo Biosciences

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.